Alnylam Pharma (ALNY) Gets a Buy Rating from Chardan Capital


Chardan Capital analyst Keay Nakae reiterated a Buy rating on Alnylam Pharma (ALNY) on February 8 and set a price target of $150. The company’s shares closed on Friday at $77.69.

According to TipRanks.com, Nakae is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -13.4% and a 29.1% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Arrowhead Research, and Dicerna Pharma.

Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $120, representing a 54.5% upside. In a report issued on February 8, Needham also maintained a Buy rating on the stock with a $135 price target.

See today’s analyst top recommended stocks >>

Based on Alnylam Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $211 million. In comparison, last year the company had a GAAP net loss of $142 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts